Our results suggest that ALKBH5, as a biomarker for predicting anti PD-L1 immunotherapy outcomes in NSCLC patients, is a potential target for addressing anti PD-L1 immunotherapy resistance in NSCLC. The gene discussed is ALKBH5; the disease is non-small cell lung carcinoma.